When will Delamanid be available?

Delamanid is approved by the European Medicines Agency (EMA) and marketed as oral tablets under the trade name Deltyba. It is marketed by Otsuka Pharmaceutical Co Ltd. (Tokyo, Japan). In 2014, Europe, Japan and South Korea approved the medical use of Delamanid, and it was included in the World Health Organization's Essential Medicines List. Delamanihas also been approved by the National Medical Products Administration in 2018 for domestic marketing.

In Phase II clinical trials, delamanid was used in combination with standard treatments, such as four or five of ethambutol, isoniazid, pyrazinamide, rifampicin, aminoglycoside antibiotics, and quinolones. Cure rates (measured as sputum culture conversion rates) were significantly better in patients who took additional delamanid. The European Medicines Agency (EMA) recommends a conditional marketing authorization for delamanib in adults with multidrug-resistant tuberculosis who have no alternative treatment options due to drug resistance or tolerance. EMA believes that the data shows that the benefits of delamanid outweigh the risks, but that additional research on long-term effectiveness is needed.

The original drug Delamani marketed in China has been included in the scope of Class B medical insurance, and is limited to reimbursement for patients with multi-drug-resistant tuberculosis. Specifications The price of 50mg*60 tablets per box may be around 6,000 yuan, which is relatively expensive. The price of the Russian version of the original drug Dramani, 50mg*48 tablets, sold overseas may be around RMB 1,000-2,000 per box (the price may fluctuate due to the exchange rate). There is currently no generic version of Dramani available on the market. For more drug information and specific prices, please consult Yaode’s medical consultant.